-
1 day ago | 
pharmacytimes.com | Alexandra Gerlach
Anitocabtagene autoleucel (anito-cel; Arcellx, Inc.) demonstrated significant response rates and minimal residual disease (MRD) negativity in patients with relapsed or refractory multiple myeloma (RRMM).
-
2 days ago | 
pharmacytimes.com | Alexandra Gerlach
The FDA and CDC made a joint announcement advising against inoculation against chikungunya infection with the Ixchiq vaccine (Valneva) for older adults ages 60 and older. The recommendation comes amid 2 fatalities and 17 adverse effects (AE), mainly neurologic and cardiac events.1Chikungunya infection is a viral illness spread through mosquito bites, more commonly found in tropical and subtropical regions of Africa, Southeast Asia, and portions of the Americas.
-
2 days ago | 
pharmacytimes.com | Alexandra Gerlach
President Donald J. Trump has signed the executive order (EO) “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” which aims to reduce drug costs for Americans and tie them to what other nations pay for medications.
-
3 days ago | 
pharmacytimes.com | Alexandra Gerlach
In this episode of the Pharmacy Times Peer Exchange feature series about antibody drug conjugates (ADCs) and human epidermal growth factor receptor 2 (HER2) breast cancer (BC), oncology pharmacists discuss novel, emerging ADCs and real-world management of these therapies.
-
5 days ago | 
pharmacytimes.com | Alexandra Gerlach
Pneumococcal disease remains a leading cause of illness and death in children globally, and although most countries have routine pneumococcal vaccination programs for infants, targeted policies for children who are at an increased risk of severe disease are far less common and highly variable. An emerging study highlights the urgent need for more consistent, detailed, and inclusive vaccination strategies to protect these vulnerable populations.
-
1 week ago | 
pharmacytimes.com | Alexandra Gerlach
The fixed-dose combination (FDC) of obicetrapib (NewAmsterdam Pharma) plus ezetimibe (Zetia; Merck and Schering-Plough Pharmaceuticals) significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with pre-existing or at high risk for atherosclerotic cardiovascular disease (ASCVD), according to data from the phase 3 TANDEM trial (NCT06005597).
-
1 week ago | 
pharmacytimes.com | Alexandra Gerlach
ISB 2001 (Ichnos Glenmark Innovation [IGI]), an investigational trispecific antibody, received fast track designation from the FDA for treatment of heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
-
1 week ago | 
pharmacytimes.com | Alexandra Gerlach
Trastuzumab deruxtecan (T-DXd, Enhertu; AstraZeneca) followed by paclitaxel (Taxol; Bristol Myers Squibb), trastuzumab (Herceptin; Genentech), and pertuzumab (Perjeta; Genentech; THP) yielded a clinically meaningful improvement in pathologic complete response (pCR) rate compared with standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) in the neoadjuvant setting in patients with high-risk, locally advanced human epidermal growth factor receptor 2-positive...
-
1 week ago | 
pharmacytimes.com | Alexandra Gerlach
Statin therapies significantly improved overall survival (OS) and progression-free survival (PFS) in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (SLL; CLL/SLL) treated with ibrutinib (Imbruvica; Janssen Biotech, AbbVie). The study findings were published in Blood Advances.1CLL is an incurable but relatively manageable leukemia with a 5-year overall survival exceeding 90% with the emergence of modern treatments.
-
1 week ago | 
pharmacytimes.com | Alexandra Gerlach
One dose of bivalent Cervarix (GlaxoSmithKline, Merck) or 9-valent Gardasil 9 (Merck) human papillomavirus (HPV) offers comparable protection compared with 2 doses, with more than 97% efficacy, according to data from the ESCUDDO trial (NCT03180034).
